pho akt signaling pathway kit Search Results


phospho akt  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc phospho akt
Phospho Akt, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phospho akt/product/Cell Signaling Technology Inc
Average 95 stars, based on 1 article reviews
phospho akt - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
two known pi3k inhibitors (byl719)  (J&K Scientific)
90
J&K Scientific two known pi3k inhibitors (byl719)
Flupentixol decreases lung cancer cell viability. (A) Flupentixol (2.5, 5, 10, 20, or 40 μM) inhibited the viability of four NSCLC cell lines (H661, A549, H520 and SK-SEM-1) in a dose-dependent manner but had little effect on BEAS-2B cells. The cells were treated with flupentixol for 24 hours, and MTT assays were performed to measure cell viability. (B) H661 and A549 cells were treated with increasing concentrations of flupentixol (2.5, 5, 10, 20, or 40 μM) for 24, 48, and 72 hours. The inhibitory effect of flupentixol in lung cancer cells was in a dose- and time-dependent manner. (C) The 24-hour cytotoxicity of flupentixol was stronger than those of two known <t>PI3K</t> inhibitors <t>(BYL719</t> and <t>BKM120)</t> in A549 and H661 cells.
Two Known Pi3k Inhibitors (Byl719), supplied by J&K Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/two known pi3k inhibitors (byl719)/product/J&K Scientific
Average 90 stars, based on 1 article reviews
two known pi3k inhibitors (byl719) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Flupentixol decreases lung cancer cell viability. (A) Flupentixol (2.5, 5, 10, 20, or 40 μM) inhibited the viability of four NSCLC cell lines (H661, A549, H520 and SK-SEM-1) in a dose-dependent manner but had little effect on BEAS-2B cells. The cells were treated with flupentixol for 24 hours, and MTT assays were performed to measure cell viability. (B) H661 and A549 cells were treated with increasing concentrations of flupentixol (2.5, 5, 10, 20, or 40 μM) for 24, 48, and 72 hours. The inhibitory effect of flupentixol in lung cancer cells was in a dose- and time-dependent manner. (C) The 24-hour cytotoxicity of flupentixol was stronger than those of two known PI3K inhibitors (BYL719 and BKM120) in A549 and H661 cells.

Journal: International Journal of Biological Sciences

Article Title: The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer

doi: 10.7150/ijbs.32625

Figure Lengend Snippet: Flupentixol decreases lung cancer cell viability. (A) Flupentixol (2.5, 5, 10, 20, or 40 μM) inhibited the viability of four NSCLC cell lines (H661, A549, H520 and SK-SEM-1) in a dose-dependent manner but had little effect on BEAS-2B cells. The cells were treated with flupentixol for 24 hours, and MTT assays were performed to measure cell viability. (B) H661 and A549 cells were treated with increasing concentrations of flupentixol (2.5, 5, 10, 20, or 40 μM) for 24, 48, and 72 hours. The inhibitory effect of flupentixol in lung cancer cells was in a dose- and time-dependent manner. (C) The 24-hour cytotoxicity of flupentixol was stronger than those of two known PI3K inhibitors (BYL719 and BKM120) in A549 and H661 cells.

Article Snippet: Flupentixol and two known PI3K inhibitors (BYL719 and BKM120) were purchased from J&K Scientific Ltd. (Beijing, China).

Techniques:

Flupentixol specifically inhibits the PI3K/AKT pathway in lung cancer cells. (A) The expression levels of p-AKT (S473 and T308) and Bcl-2 were decreased by flupentixol in a dose-dependent manner. A549 and H661 cells were treated with increasing concentrations of flupentixol (2.5, 5, 10 or 15 μM) for 24 hours. Flupentixol had no effect on PI3K p110ɑ, t-AKT, p-ERK, t-ERK, VEGF, or MMP-9. (B) The inhibitory effects of two known PI3K inhibitors (BYL719 and BKM120) on the expression of p-AKT, t-AKT, and Bcl-2 in A549 and H661 cells.

Journal: International Journal of Biological Sciences

Article Title: The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer

doi: 10.7150/ijbs.32625

Figure Lengend Snippet: Flupentixol specifically inhibits the PI3K/AKT pathway in lung cancer cells. (A) The expression levels of p-AKT (S473 and T308) and Bcl-2 were decreased by flupentixol in a dose-dependent manner. A549 and H661 cells were treated with increasing concentrations of flupentixol (2.5, 5, 10 or 15 μM) for 24 hours. Flupentixol had no effect on PI3K p110ɑ, t-AKT, p-ERK, t-ERK, VEGF, or MMP-9. (B) The inhibitory effects of two known PI3K inhibitors (BYL719 and BKM120) on the expression of p-AKT, t-AKT, and Bcl-2 in A549 and H661 cells.

Article Snippet: Flupentixol and two known PI3K inhibitors (BYL719 and BKM120) were purchased from J&K Scientific Ltd. (Beijing, China).

Techniques: Expressing